The Latest Breaking News from FDA

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

MarketBeat · Feb 20

This High-Yield Dividend King Has 56 Years of Raises and Wall Street Is Screaming ‘Buy’

This 56-year Dividend King yields 6.3%, carries a Moderate Buy rating, and could offer steady income plus upside despite industry shifts.

Barchart · Feb 20

Menstrual pads and tampons can contain toxic substances – here’s what to know about this emerging health issue

About half of the global population menstruates at some point in their lives. Disposable products, such as tampons and pads, are some of the most popular products used around the globe to manage menstrual flow.

The Conversation · Feb 20

What Vets Wish Indian Pet Owners Knew About Pet Nutrition ?

The Fundamentals of Feeding Your Pet:

Proper nutrition results in a shiny coat, strong immunity, and an active lifestyle in pets.

When you bring your pet in for a check-up, your vet is doing a visual and hands-on assessment, and it all boils down to one thing: Is this diet…

Times Pets · Feb 19

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from public health experts.

The Conversation · Feb 18

FDA issues urgent recall of trendy supplement after three people fall ill in US

Three people with salmonella infections said they had taken the supplements

The Independent UK · Feb 18

FDA will drop two-study requirement for new drug approvals, aiming to speed access

The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals

The Independent UK · Feb 18

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

Moderna shares extend gains as FDA reverses its refusal-to-file decision on the firm’s influenza vaccine. Here’s why MRNA shares still aren’t attractive to own in 2026.

Barchart · Feb 18

FDA reverses course and will review Moderna’s mRNA-based flu vaccine

US drug regulator originally refused to consider application, fueling critics’ concern about alleged ‘anti-vaccine agenda’

The Guardian - US · Feb 18

FDA removes page warning against fake autism ‘treatments’ like raw camel milk and chlorine dioxide

FDA page once warned people against using ‘miracle mineral supplement’ which contains chlorine dioxide – a dangerous chemical

The Independent UK · Feb 18